...
首页> 外文期刊>Ophthalmic epidemiology >Statin use and the risk of age related macular degeneration in a large health organization in Israel.
【24h】

Statin use and the risk of age related macular degeneration in a large health organization in Israel.

机译:以色列一家大型卫生组织的他汀类药物的使用以及与年龄相关的黄斑变性的风险。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: To investigate the association between persistent use of statins and the risk of age-related macular degeneration (AMD). DESIGN: A population-based retrospective cohort among adults who began statin therapy between 1998 and 2006 in a large health organization in Israel. The organization's central computerized databases were used to collect data on incident AMD cases diagnosed by ophthalmologists. RESULTS: A total of 108,973 individuals aged 55 or older were identified. During the study follow-up period 409,113 person-years, there were 2,732 incident AMD cases (6.68 per 1,000 person-years). The crude incidence density rate of AMD among patients at the lowest quintile of persistence with statins (7.18 per 1,000) was comparable to that of highest persistence quintile (7.13 per 1,000). After adjustment for potential confounders, patients in the highest quintile of persistence with statins had a hazard ratio of 0.99 (95% Confidence Interval: 0.78-1.26) for AMD compared with patients in the lowest proportion of days covered (PDC) quintile. In addition to age, AMD was found to associate with past smoking, asthma, diabetes and frequent visits to ophthalmologists or primary physicians prior to index date. CONCLUSIONS: Our study agrees with previous studies that showed no association between persistent use of statins and reduced risk of AMD. These results suggest that the early reports on a strong protective effect of statins against AMD development were probably a result of a small study effect.
机译:目的:研究持续使用他汀类药物与年龄相关性黄斑变性(AMD)风险之间的关系。设计:一项基于人群的回顾性队列研究,该队列研究对象是在1998年至2006年间在以色列一家大型卫生组织中开始他汀类药物治疗的成年人。该组织的中央计算机数据库被用来收集眼科医生诊断出的AMD事件的数据。结果:总共确定了108,973个人,年龄在55岁以上。在研究随访期409,113人年期间,发生了2,732例AMD事件(每千人年6.68例)。在他汀类药物持久性最低的五分之一患者中,AMD的粗略发病率密度(每千人中7.18)与最高持久性五分位数的患者(每千人中7.13)可比。在对潜在的混杂因素进行调整后,与他汀类药物覆盖天数最低(PDC)比例最低的患者相比,持他汀类药物持久性最高的五分之一患者的AMD危险比为0.99(95%置信区间:0.78-1.26)。除年龄外,还发现AMD与过去吸烟,哮喘,糖尿病以及在索引日期之前频繁拜访眼科医生或主治医师有关。结论:我们的研究与以前的研究一致,后者表明持续使用他汀类药物与降低AMD风险之间没有关联。这些结果表明,关于他汀类药物对AMD发育具有强保护作用的早期报道可能是小研究结果的结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号